Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92792 citas

 
 
 1 a 7 de 7 
Presentar resultados
Seleccionar todas
1.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
2.Tiene citas relacionadas Cita con resumen
Lennox JL, DeJesus E, Lazzarín A, Pollard RB, Madruga J, Berger DS, Zhao J, Xu X, Williams-Díaz A, Rodgers AJ, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Sklar P, for the STARTMRK investigators. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009;374:796-806. [Ref.ID 86738]
3.Tiene citas relacionadas
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarín A, Clotet B, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Teppler H, Nguyen B-Y, for the BENCHMRK Study Teams. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359:355-65. [Ref.ID 83712]
4.Tiene citas relacionadas
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarín A, Clotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen B-Y, Teppler H, for the BENCHMRK Study Teams. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339-54. [Ref.ID 83711]
5.Tiene citas relacionadas Cita con resumen
Gallant JE, Stazewski S, Pozniak A, DeJesus E, Suleiman JMAH, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, for the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-yer randomized trial. JAMA 2004;292:191-201. [Ref.ID 70702]
6.
Squires K, Pozniak A L, Pierone G, Steinhart CR, Berger D, Bellos NC, Becker SL, Wulfsohn M, Miller MD, Toole JJ, Coakley DF, Cheng A. Tenofovir disoproxil fumarate in nucleoside-resistant HIV-1 infection. A randomized trial. Ann Intern Med 2003;139:313-20. [Ref.ID 67290]
7.
Reynolds III C F, Frank E, Perel J M, Imber SD, Cornes C, Miller MD, Mazumdar S, Houck PR, Dew MA, Stack JA, Pollock B G, Kupfer DJ. Nortriptyline and interpersonal psychotherapy as maintenance therapy for recurrent major depression. A randomized controlled trial in patients older than 59 years. JAMA 1999;281:39-45. [Ref.ID 42447]
Seleccionar todas
 
 1 a 7 de 7